EQUIPEngadget · 1h ago
FDA approves Moderna's mRNA flu vaccine after initially refusing to review it
Executive Brief
The 30-second read
The FDA has granted approval for Moderna's mRNA-based seasonal flu vaccine, reversing its initial refusal to review the application. This regulatory milestone introduces mRNA technology into the seasonal influenza market to potentially improve immunization efficacy.
- 01FDA approves Moderna seasonal mRNA flu vaccine following a previous refusal to review
- 02Approval marks a strategic expansion of mRNA technology into the global influenza market
- 03Regulatory clearance follows an initial period of administrative or clinical uncertainty
- 04New vaccine platform offers a potential alternative to traditional egg-based manufacturing methods
Go deeper · Equip playbook
Business Travel Management 2026: Program Blueprint →AI-generated summary · Verify at source
After refusing to even review it, the FDA has approved Moderna's mRNA seasonal flu vaccine.